Objective: To comparatively analyze the efficacy, acceptability, and tolerability of various
augmentation agents in adult patients with treatment-resistant depression. Data Sources: An …

Glycogen synthase kinase-3 (GSK3) has recently been linked to mood disorders and
schizophrenia, and the neurotransmitter systems and therapeutic treatments associated with …

Objective: The delayed onset of therapeutic response and the high number of
nonresponders to antidepressants remain major clinical problems in depressive disorders …

Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients
respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap …

Bipolar disorder is a serious psychiatric condition that has been treated for over 50 years
with lithium. Lithium is a well established glycogen synthase kinase-3 (GSK-3) inhibitor …

Background: The late onset of therapeutic response and a relatively large proportion of
nonresponders to antidepressants remain major concerns in clinical practice. Therefore …

BACKGROUND: Two promising approaches have been introduced for the prediction of
treatment response in major depression: one concept is based on the activity in the rostral …

The criteria used to assess whether a problem is of public health importance (and therefore
should be a priority for health services) include the prevalence of the problem, the severity of …

Introduction: Selective serotonin and norepinephrine reuptake inhibitors (SNRI) are among
the most prescribed antidepressants, and dose escalation is a frequently applied strategy …

Abstract Treatment response and resistance in major depressive disorder (MDD) are
suggested to be heritable. Due to significant challenges in defining treatment-related …